Edinburgh, Scotland and Newtown, PA, U.S.A, February 25, 2013 -- Quotient Biodiagnostics (“Quotient”), a global transfusion diagnostics group, is pleased to announce that its shareholders have invested a further $5.0 million in the company. Over the past 18 months Quotient has raised over $19 million of new equity.
NEWTOWN, PA (January 30, 2013) Quotient Biodiagnostics, Inc., dedicated to providing high quality immunohematology products to blood banks and hospitals, today announced that it has entered into a 36 month Laboratory Solutions supply with Amerinet Inc.. The agreement is effective January 1st, 2013 and includes Quotient’s complete range of blood bank reagents at specially negotiated pricing and terms.
NEWTOWN, PA., October 2nd, 2012 – Quotient Biodiagnostics, Inc. (“Quotient”), a supplier of innovative and high-quality transfusion diagnostic products to hospitals, blood banks and other healthcare institutions, is pleased to announce that its range of ALBAsera® Rare Antisera products have been licensed for sale by the U.S. Food and Drug Administration (FDA).
NEWTOWN, PA (August 15, 2012) Quotient Biodiagnostics, Inc., dedicated to providing high quality immunohematology products to blood banks and hospitals, today announced that it has entered into a 36 month supply agreement with Premier healthcare alliance. The agreement is effective November 1st, 2012 and includes Quotient’s complete range of blood bank reagents, including its recently launched ALBAcyte® line of reagent red blood cell products, at specially n…
Newtown, PA and Edinburgh, Scotland, March 5, 2012 /PR Newswire/ -- Quotient Biodiagnostics Holdings Limited (“Quotient”), a global transfusion diagnostics Group, is pleased to announce that it has completed an $11.2 million growth equity financing led by Galen Partners, a US-based healthcare venture capital investment firm.
NEWTOWN, PA., January 16th, 2012 – Quotient Biodiagnostics, Inc. (“Quotient”), a supplier of innovative and high-quality transfusion diagnostic products to hospitals, blood banks and other healthcare institutions, is pleased to announce that its range of ALBAcyte® Reagent Red Blood Cell products have been licensed for sale in the USA by the Food and Drug Administration (FDA).
“Licensing of the ALBAcyte® Reagent Red Blood Cell products by the FDA satisfi…
Quotient now an approved vendor for Veteran's Affairs, Indian Health Services, and other government hospitals through General Services Agency Contract
NEWTOWN, PA (December 1, 2011) Quotient Biodiagnostics, Inc., dedicated to providing high quality immunohematology products to blood banks and hospitals, today announced that it has been awarded a five year contract to supply its blood bank reagents to the federal government. Through the Federal Supply Schedule, Quotient…
ATTENDEES RATE PROGRAM 3.9 OUT OF 4.0
NEWTOWN, PA (October 24, 2011) Quotient Biodiagnostics, Inc., dedicated to providing high quality immunohematology products to blood banks and hospitals, today hosted an Industry Workshop entitled "The Myth and Mystery of RhD" at the 2011 Annual Meeting of the AABB. The program consisted of three presentations by an august set of panelists.
BGA is a Buying Cooperative Representing 69 Independent Blood Center Members
December 13, 2010
NEWTOWN, PA (December 13, 2010 Quotient Biodiagnostics, Inc., dedicated to providing high quality immunohematology products to blood banks and hospitals, today announced that it has entered into a supply agreement with Blood Group Alliance (BGA). BGA will promote Quotient’s product line to its blood center member organizations, which account for over 50% percent of the nation’…
November 01, 2010
NEWTOWN, PA. (November 1, 2010) - Quotient Biodiagnostics, Inc., dedicated to providing high quality immunohematology products to hospitals and blood banks, today announced that it had launched two new products including: ALBAcyte® IgG Sensitized Cells and ALBAlect® Anti-A1 Lectin.
New ALBAcyte® IgG Sensitized Cells can cost 40-60% less than primary competitors.
